SILODOSIN THERAPY FOR LOWER URINARY TRACT SYMPTOMS IN MEN WITH SUSPECTED BENIGN PROSTATIC HYPERPLASIA: RESULTS OF AN INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBOAND ACTIVE-CONTROLLED CLINICAL TRIAL PERFORMED IN EUROPE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Silodosin is a new selective therapy with a high pharmacologic selectivity for the a 1A-adrenoreceptor. Objective: Our aim was to test silodosin’s superiority to placebo and noninferiority to tamsulosin and discuss the findings in the context of a comprehensive literature review of the new compound silodosin. Design, setting, and participants: We conducted a multicenter doubleblind, placebo-and active-controlled parallel group study. A total of 1228 men ≥50 yr of age with an International Prostate Symptom Score (IPSS) ≤13 and a urine maximum flow rate (Q max)>4 and <15 ml/s were selected at 72 sites in 11 European countries. The patients were entered into a 2-wk wash-out and a 4-wk placebo run-in period. A total of 955 patients were randomized (2:2:1) to silodosin 8 mg (n=38l), tamsulosin 0.4 mg (n=384), or placebo (n=l90) once daily for 12 wk. Measurements: We calculated the change from baseline in IPSS total score (primary), storage and voiding subscores, quality of life (QoL) due to urinary symptoms, and Q max. Responders were defined on the basis of IPSS and by Q maxa decrease of ≥25% and an increase of ≥30% from baseline, respectively. Results and limitations: The change from baseline in the IPSS total score with silodosin and tamsulosin was significantly superior to that with placebo ( p< 0.001): difference active placebo of -2.3 (95% confidence interval [CI], -3.2, -1.4) with silodosin and -2.0 (95% CI, -2.9, -1.1) with tamsulosin. Responder rates according to total IPSS were significantly higher ( p<0.00l) with silodosin (66.8%) and tamsulosin (65.4%) than with placebo (50.8%). Active treatments were also superior to placebo in the IPSS storage and voiding subscore analyses, as well as in QoL due to urinary symptoms. Of note, only silodosin significantly reduced nocturia versus placebo (the change from baseline was -0.9, -0.8, and -0.7 for silodosin, tamsulosin, and placebo, respectively; p=0.0l3 for silodosin vs placebo). An increase in Q max was observed in all groups. The adjusted mean change from baseline to end point was 3.77 ml/s for silodosin, 3.53 ml/s for tamsulosin, and 2.93 ml/s for placebo, but the change for silodosin and tamsulosin was not statistically significant versus placebo because of a particularly high placebo response (silodosin vs placebo: p=0.089; tamsulosin vs placebo: p=0.22l). At end point, the percentage of responders by Q max was 46.6%, 46.5%, and 40.5% in the silodosin, tamsulosin, and placebo treatment groups, respectively. This difference was not statistically significant (p=0.l55 silodosin vs placebo and p=0.l4l tamsulosin vs placebo). Active treatments were well tolerated, and discontinuation rates due to adverse events were low in all groups (2.1%, 1.0%, and 1.6% with silodosin, tamsulosin, and placebo, respectively). The most frequent adverse event with silodosin was a reduced or absent ejaculation during orgasm (14%), a reversible effect as a consequence of the potent and selective a lA-adrenoreceptor antagonism of the drug. The incidence was higher than that observed with tamsulosin (2%); however, only 1.3% of silodosin-treated patients discontinued treatment due to this adverse event. Conclusions: Silodosin is an effective and well-tolerated treatment for the relief of both voiding and storage symptoms in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction thought to be associated with benign prostatic hyperplasia. Its overall efficacy is not inferior to tamsulosin. Only silodosin showed a significant effect on nocturia over placebo.

Full Text

Restricted Access

References

  1. www.sciencedirect.com
  2. Chapple C. Medical treatment for benign prostatic hyperplasia. BMJ 1992;304:1198-1199.
  3. Clifford G. M., Farmer R. D. T. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000;38:2-19.
  4. Barry M. J., Cockett A. T., Holtgrewe H. L. et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150:351-358.
  5. Peters T. J., Donovan J. L., Kay H. E. et al. The International Continence Society ‘‘Benign Prostatic Hyperplasia” Study: the botherosomeness of urinary symptoms. J Urol 1997;157:885-889.
  6. Madersbacher S., Alivizatos G., Nordling J., Rioja Sans C., Emberton M., de la Rosette JJMCH. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-554.
  7. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2007;9:181-190.
  8. Chapple C. R. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practicing clinician. BJU Int 2004;94:738-744.
  9. Lepor H., Auerbach S., Puras-Baez A. et al. A randomised, placebocontrolled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467-1474.
  10. Chapple C. R., Carter P., Christmas T. J. et al. A three-month doubleblind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. J Urol 1994;74:50-56.
  11. Michel M. C., Grübbel B., Möllhoff S, et al. 1-Adrenoceptor affinities of drugs for the treatment of benign prostatic hyperplasia in human prostate, rat tissues and at cloned subtypes. Abstract presented at: 23rd Congress of the Société Internationale d’Urologie; September 18-24, 1994; Sydney, Australia. Abstract 649.
  12. Hatano A., Takahashi H., Tamaki M., Komeyama T., Koizumi T., Takeda M. Pharmacological evidence of district α1-adrenoceptors subtypes mediating the contraction of human urethra and peripheral artery. Br J Pharmacol 1994;113:723-728.
  13. Tatemichi S., Kobayashi K., Maezawa A. et al. a1-Adenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 2006;126:209-216.
  14. Akiyama K., Hora M., Tatemichi S. et al. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 1999;291:81-91.
  15. Akiyama K., Noto H., Nishizawa O. et al. Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 2001;8: 177-183.
  16. Kawabe K., Yoshida M., Homma Y. Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-1024.
  17. Marks L.S., Gittelman M.C., Hill L.A., Volinn W., Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-2640.
  18. Chapple C., Andersson K.E. Tamsulosin: an overview. World J Urol 2002;19:397-404.
  19. Marks L. S., Gittelman M. C., Hill L. A., Volinn W., Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009;74: 1318-1322.
  20. Kobayashi S., Tomiyama Y., Tatemichi S., Hoyano Y., Kobayashi M., Yamazaki Y. Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia. Eur J Pharmacol 2009;613:135-140.
  21. MacDiarmid S.A., Hill L.A., Volinn W., Hoel G. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 2010; 75: 520-525.
  22. van Dijk M. M., de la Rosette JJMCH, Michel M.C. Effects of alpha-1 adrenoceptor antagonists on male sexual function. Drugs 2006;66: 287-301.
  23. Furukawa K., Rosario D. J., Smith D. J., Chapple C. R., Uchiyama T., Chess-Wiliams R. Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol 1995;116: 1605-1610.
  24. Michel M. C., Hanft G., Groß G. Functional studies on alpha- 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol 1994;111:539-546.
  25. Noble A. J., Chess-Williams R., Couldwell C. et al. The effects of tamsulosin, a high affinity antagonist at functional a1A- and a1D-adrenoceptor subtypes. Br J Pharmacol 1997;120:231-238.
  26. Leonardi A., Hieble J. P., Guarneri L. et al. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther 1997;281:1272-1283.
  27. Giuliano F. A., Clement P., Denys P., Alexandre L., Bernabe J. Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats. BJU Int 2006;98:876-879.
  28. Miller J., Carson C. C. Alpha blockers and ejaculatory function: a state of the art review. Curr Sex Health Rep 2007;4:141-144.
  29. Sanbe A., Tanaka Y., Fujiwara Y. et al. a1-Adrenoceptors are required for normal male sexual function. Br J Pharmacol 2007;152:332-340.
  30. Michel M. C. a1-Adrenoceptors and ejaculatory function. Br J Pharmacol 2007;152:289-290.
  31. Hisasue S., Furuya R., Itoh N., Kobayashi K., Furuya S., Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 2006;13:1311-1316.
  32. Kobayashi K., Masumori N., Hisasue S. I. et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective a1A-blocker in normal volunteers. J Sex Med 2008;5:2185-190.
  33. Hellstrom W. J., Giuliano F., Rosen R. C. Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment. Urology 2009;74:15-21.
  34. Blanker M. H., Bosch J. L., Groeneveld F. P. et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50-78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57:763-8.
  35. Blanker M. H., Bohnen A. M., Groeneveld F. P. et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a communitybased study. J Am Geriatr Soc 2001;49:436-442.
  36. Rosen R., Altwein J., Boyle P. et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003;44:637-649.
  37. Roehrborn C. G., Lepor H., Kaplan S. A. Retrograde ejaculation induced by silodosin is the result of relaxation of smooth musculature in the male urogenital tract and is associated with greater urodynamic and symptomatic improvement in male LUTS secondary to BPH. J Urol 2009;181. Abstract 1922.
  38. Homma Y., Kawabe K., Takeda M., Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010;76:1446-1450.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2012 Bionika Media